Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in children with pulmonary arterial hypertension
NCT02932410Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2017
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Oct 2017; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02932410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932410.